Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease
· Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones · Foliglurax is a first-in-class treatment which entered clinical phase II testing in Parkinson’s disease in July 2017 · There remains a large unmet need for effective treatments for Parkinson’s patients to sustain the utility of dopaminergic therapies Valby, Denmark, Oss, The Netherlands, 16 March 2018 - H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) today announced signing of a definitive agreement in